Welcome to our dedicated page for CNS Pharmaceuticals SEC filings (Ticker: CNSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CNS Pharmaceuticals SEC filings document the regulatory record for a clinical-stage pharmaceutical company developing therapies for brain and central nervous system cancers. Its filings cover material-event reports, Regulation FD investor presentations, operating and financial updates, clinical and regulatory disclosures, and capital-structure information for its Nasdaq-listed common stock.
The company’s proxy and 8-K filings also describe governance matters, annual-meeting votes, equity-plan amendments, officer appointments, employment agreements and related compensation arrangements. These disclosures frame the company’s formal reporting around pipeline strategy, corporate leadership, stockholder approvals and public-company controls.
CNS Pharmaceuticals director Charles L. Faith reported an open-market purchase of 7,100 shares of Common Stock. The shares were bought at a price of $4.789 per share on May 18, 2026, and he now directly holds 7,100 shares following this transaction.
CNS Pharmaceuticals, Inc. files a registration statement to register for resale up to 9,793,479 shares of Common Stock. The amount consists of 650,000 shares issued in a May private placement and 9,143,479 shares issuable upon exercise of Pre-Funded Warrants exercisable at $0.001 per share. The Company states it will not receive proceeds from resales by the Selling Shareholders and that it received gross proceeds of approximately $22.5 million from the private placement closed May 5, 2026. Shares outstanding were 1,461,449 as of May 14, 2026. The Registration Rights Agreement required filing this registration statement and the Company agreed to limited standstill and timing restrictions described herein.
CNS Pharmaceuticals, Inc. Schedule 13G/A amendment discloses that Stonepine-affiliated reporting persons beneficially own 159,790 shares of Common Stock, representing 9.9% of the class. The reporting persons state these holdings consist of 21,738 shares of Common Stock and warrants to purchase 1,304,348 shares, and the percentage is calculated using 1,461,449 shares outstanding as of May 13, 2026.
The filing lists shared voting and dispositive power over 159,790 shares across Stonepine Capital Management, the Partnership, Stonepine GP and Jon M. Plexico. The Partnership holds the Common Stock for the benefit of its investors, and the reporting persons disclaim group membership and broader beneficial ownership beyond their pecuniary interest.
CNS Pharmaceuticals reported a wider quarterly loss as it pivots strategy but shored up liquidity after quarter-end. For the three months ended March 31, 2026, the company recorded a net loss of about $4.9 million, compared with $4.3 million a year earlier, driven mainly by higher research and development and professional expenses.
Cash and cash equivalents fell to $2.95 million with a working capital deficit of roughly $0.5 million as of March 31, 2026, and operating cash use rose to about $4.6 million. A May 2026 private placement then generated gross proceeds of approximately $22.5 million through common stock and pre-funded warrants, which management believes will fund operations beyond 12 months from issuance of these financial statements.
The company announced a new corporate strategy in March 2026 to pursue innovative therapies for serious diseases, moving away from a sole focus on glioblastoma and exploring out-licensing of legacy assets TPI 287 and Berubicin. CNS Pharmaceuticals continues to report a material weakness in internal control over financial reporting and is adding senior executives, including a new CEO, CFO, Chief Medical Officer and Chief Technology Officer, while providing severance to departing leaders.
CNS Pharmaceuticals, Inc. entered into a private placement with institutional investors, selling 650,000 shares of common stock at $2.30 per share and issuing pre-funded warrants for 9,143,479 shares at $2.299 per warrant. Gross proceeds are expected to be approximately $22.5 million before fees.
The pre-funded warrants are exercisable immediately at $0.001 per share, subject to a 4.99% or 9.99% beneficial ownership cap, and remain outstanding until fully exercised. The company plans to use net proceeds to identify, acquire, and advance new assets and for working capital and general corporate purposes.
CNS Pharmaceuticals agreed to register the resale of the shares and underlying warrant shares and accepted restrictions on additional equity sales and variable rate transactions for specified periods. The company also announced the resignation of director Jerzy (George) Gumulka and the appointment of life sciences executive Michal Fisher as an independent board member.
CNS Pharmaceuticals, Inc. filed an amended annual report to add updated Part III information on directors, executive compensation, ownership and auditor matters for the year ended December 31, 2025. The filing does not change prior financial statements and should be read together with the original Form 10-K.
The company reports aggregate market value of voting equity held by non-affiliates of $8.78 million and 811,449 common shares outstanding as of April 27, 2026. It details a leadership transition from former CEO John Climaco to new CEO Rami Levin and provides 2025 compensation data, board committee composition, equity plan usage and auditor fee disclosures.
CNS Pharmaceuticals, Inc. ownership disclosure: Ikarian Capital, LLC and Neil Shahrestani report shared beneficial ownership of 45,830 shares of Common Stock, representing 5.7% of the class. The stake is held via Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts, with 811,449 shares outstanding as of March 31, 2026 as disclosed in the issuer's Form 10-K.
The filing states that Ikarian Capital exercises investment discretion for the Fund and managed accounts and that Mr. Shahrestani may be deemed to beneficially own the securities indirectly; the Fund and the Managed Accounts disclaim cross-beneficial ownership.
CNS Pharmaceuticals, Inc. is a clinical-stage biotechnology company pivoting from a historical focus on glioblastoma to building an in-licensed pipeline in neurology and oncology. A new CEO took over on January 1, 2026, followed by a rebuilt executive team effective March 2, 2026, and a new growth strategy announced on March 11, 2026.
The company plans to out-license its legacy GBM assets TPI 287 and Berubicin after Berubicin’s Phase 2 trial failed to show superiority over lomustine in overall survival. As of December 31, 2025, CNS held cash of about $7,201,000 and working capital of roughly $4,002,000, expects its cash to fund operations into the third quarter of 2026, and reported an accumulated deficit of $100,275,268.
The independent auditor expressed substantial doubt about the company’s ability to continue as a going concern. Non‑affiliate voting equity was valued at approximately $5.0 million as of the last business day of the most recently completed second fiscal quarter, and 811,449 common shares were outstanding as of March 31, 2026. CNS had eight full‑time employees and will require significant additional capital to execute its licensing-focused strategy and continue operations.
CNS Pharmaceuticals, Inc. furnished an investor presentation outlining a new corporate growth strategy led by a recently installed executive team. The company is pivoting to focus on high-value neurology and oncology markets, emphasizing data-driven, capital-efficient development and targeting assets with strong biological rationale and near-term catalysts.
The strategy includes a formal global search for differentiated preclinical and clinical-stage programs, while positioning legacy glioblastoma multiforme programs such as Berubicin and TPI 287 for potential out-licensing. Management highlights neurology and oncology as large, growing therapeutic areas with significant unmet needs and active deal flow.
Faulkner Eric reported acquisition or exercise transactions in this Form 4 filing.
CNS Pharmaceuticals granted Chief Technology Officer Eric Faulkner 9,500 restricted stock units on March 2, 2026. Each unit represents a contingent right to receive one share of common stock. The award was issued in connection with his employment.
The RSUs vest over time: 25% after six months, another 25% after twelve months, and the remaining 50% in twelve quarterly installments thereafter, provided he remains employed on each vesting date. This is a stock-based compensation grant rather than an open-market share purchase.